E46: Atul Rustgi of Accolade on What is LP Value-Add and Can it Lead to Alpha?
Atul Rustgi sits down with David Weisburd to discuss his role as a GP & LP, the paradoxes of selling and building relationships in VC, and the strategy of focusing on funds under $100 million. They also delve into including biotech as a diversification strategy, the importance of blockchain and crypto exposure, family…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from How I Invest with David Weisburd
See all episodes →
E433: AlphaSense’s Chris Ackerson on AI, the Future of Finance & Finding Alpha
E432: $24 Billion Investor on Private Credit, the Psychology of Winning & Fear of Failure
E431: Marty Kausas on AI, Trillion Dollar Startups & Founder Psychology
Similar episodes from other shows
More like How I Invest with David Weisburd →
20VC: Portfolio Construction, Optimising SPVs, Opportunity Investing "Between Rounds", Being Distribution-Centric Over Product-Centric and Capital Concentration Within Funds With Sumeet Gajri, Chief Strategy Officer @ Carta
Ben Horowitz on Raising a New Fund and How Venture Firms Scale
59%Felicis founder Aydin Senkut: why moats are dead and alive
Venture Capital During the AI Revolution with Mamoon Hamid
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.